论文部分内容阅读
目的:探讨多西他赛固体脂质纳米粒抗乳腺癌效果及机制研究。方法:本实验采用MTT法考察了多西他赛固体脂质纳米粒对人乳腺癌MCF-7细胞增殖的抑制作用,采用流式细胞术检测多西他赛固体脂质纳米粒对MCF-7肿瘤细胞凋亡作用,并进一步应用Western-Blot印迹法观察多西他赛固体脂质纳米粒对MCF-7细胞中Src、E-cadherin、β-catenin蛋白表达的影响,探索了其抗乳腺肿瘤的作用机制。结果:多西他赛固体脂质纳米粒能够显著抑制人乳腺癌MCF-7肿瘤细胞的增殖,且浓度越高,抑制率越大(P<0.05)。经25、50、100μg/m L多西他赛固体脂质纳米粒制剂作用24 h后,人乳腺癌细胞MCF-7的凋亡率分别为14.56%、21.21%、29.94%,细胞凋亡率随着药物浓度的增加而增加,且各实验组间比较有显著性差异(P<0.05)。人乳腺癌MCF-7肿瘤细胞经不同浓度的多西他赛固体脂质纳米粒处理后,细胞中E-cadherin蛋白表达显著升高,Src、β-catenin蛋白表达显著降低,且呈现出明显的剂量依赖性。结论:多西他赛固体脂质纳米粒能够抑制人乳腺癌MCF-7细胞增殖,促进其凋亡,可能与下调β-catenin蛋白的表达,上调E-cadherin蛋白表达以及抑制Src激酶活性有关。
Objective: To investigate the anti-breast cancer effect and mechanism of docetaxel solid lipid nanoparticles. Methods: The inhibitory effect of docetaxel solid lipid nanoparticles on the proliferation of human breast cancer MCF-7 cells was investigated by MTT assay. The effect of docetaxel solid lipid nanoparticles on the proliferation of MCF-7 cells was detected by flow cytometry The effect of docetaxel solid lipid nanoparticles on the expression of Src, E-cadherin and β-catenin in MCF-7 cells was further investigated by western blotting. The anti-tumor activity of breast cancer cells The mechanism of action. Results: Docetaxel solid lipid nanoparticles could significantly inhibit the proliferation of MCF-7 human breast cancer cells. The higher the concentration, the higher the inhibition rate (P <0.05). The apoptotic rates of human breast cancer cell MCF-7 were 14.56%, 21.21%, 29.94% respectively after 25, 50, 100μg / ml docetaxel solid lipid nanoparticles were administered for 24 hours. The apoptotic rate With the increase of drug concentration, there was a significant difference between the experimental groups (P <0.05). After treated with different concentrations of docetaxel solid lipid nanoparticles, the expression of E-cadherin protein and the expression of Src and β-catenin in human breast cancer MCF-7 cells were significantly decreased Dose-dependent. CONCLUSION: Docetaxel solid lipid nanoparticles can inhibit the proliferation and promote apoptosis of human breast cancer MCF-7 cells, which may be related to down-regulation of β-catenin protein expression, up-regulation of E-cadherin protein expression and inhibition of Src kinase activity.